^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

GPR183 (G Protein-Coupled Receptor 183)

i
Other names: GPR183, G Protein-Coupled Receptor 183, EBV-Induced G-Protein Coupled Receptor 2, EBI2, Epstein-Barr Virus Induced Gene 2 (Lymphocyte-Specific G Protein-Coupled Receptor), Epstein-Barr Virus-Induced G-Protein Coupled Receptor 2, G-Protein Coupled Receptor 183, HEBI2
Associations
Trials
1m
Paclitaxel induces trained immunity via the GPR183-STING axis to enhance host defense against MRSA infection. (PubMed, Vet Res)
In a murine MRSA pneumonia model, PTX-trained mice showed reduced bacterial burden, preserved lung barrier integrity, and enhanced immune activation, all of which were reversed by GPR183 inhibition or STING deficiency. Collectively, our findings uncover a previously unrecognized immunomodulatory function of PTX and highlight the therapeutic potential of targeting the GPR183-STING axis to enhance trained immunity against resistant bacterial infections.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • STING (stimulator of interferon response cGAMP interactor 1) • GPR183 (G Protein-Coupled Receptor 183)
|
paclitaxel
2ms
CD Molecules Nomenclature 2025: Antibody Validation and Expression Profiling of Immune System G Protein-Coupled Receptors. (PubMed, Eur J Immunol)
We detail the quantitative expression profiles of these molecules on various subsets of leukocytes and provide validation data for these mAbs. The implications of these expression profiles are discussed for the potential therapeutic targeting of immune-mediated diseases and cancer.
Journal
|
CD74 (CD74 Molecule) • CCR8 (C-C Motif Chemokine Receptor 8) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • FPR2 (Formyl Peptide Receptor 2) • GPR183 (G Protein-Coupled Receptor 183)
7ms
G-protein coupled receptor 183 (GPR183) inhibits visceral metastasis of non-small cell lung cancer. (PubMed, Clin Exp Metastasis)
In the mouse model, GPR183 significantly reduced metastatic burden. These findings suggest that GPR183 inhibits NSCLC visceral metastasis by modulating angiogenesis and metastatic pathways, presenting a potential therapeutic target for preventing brain metastasis in lung cancer patients.
Journal
|
GPR183 (G Protein-Coupled Receptor 183)
11ms
Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptors. (PubMed, bioRxiv)
Based on Perturb-seq and functional investigations, GPR183 also enhances effector functions, such that engineering NK and CAR NK cells to express GPR183 enhances their ability to migrate to, infiltrate, and control breast cancer tumors. Our study uncovered metabolite-based tumor immune recruitment mechanisms, opening avenues for spatially targeted cell therapies.
Journal
|
FPR3 (Formyl Peptide Receptor 3) • GPR183 (G Protein-Coupled Receptor 183)
1year
High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia. (PubMed, Biochem Genet)
The results suggested that GPR183 may influence disease progression through the activation of the "TNFa Signaling Via NF-κB" pathway. Collectively, these findings suggested that GPR183 could serve as a valuable prognostic biomarker in CN-AML, offering insights into the underlying mechanisms of disease progression.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • GPR183 (G Protein-Coupled Receptor 183)
1year
Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes. (PubMed, Cell)
Finally, we demonstrate that LN CCL19 is critical in lymphocyte recruitment during inflammation. Thus, our work explains how naive precursor trafficking is sustained in responding LNs, identifies a role for oxysterols in cell recruitment into inflamed tissues, and establishes a logic for the CCR7 two-ligand system.
Journal
|
CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21) • GPR183 (G Protein-Coupled Receptor 183)
1year
Exploring G Protein-Coupled Receptors in Hematological Cancers. (PubMed, ACS Pharmacol Transl Sci)
Furthermore, we explored missense mutations of pediatric ALL in relation to the RNA gene expression findings, providing insights into the genetic underpinnings of this disease. By integrating both RNA-seq and missense mutation data, this article aims to provide an insightful and broader perspective on the potential correlations between specific GPCR and their roles in pediatric ALL.
Journal
|
GPRC6A (G Protein-Coupled Receptor Class C Group 6 Member A) • GPR183 (G Protein-Coupled Receptor 183)
over1year
Oxysterols in tumor immune microenvironment (TIME). (PubMed, J Steroid Biochem Mol Biol)
Certain oxidized steroids can increase both the number and activation of infiltrating T cells, synergizing with anti-PD-1 to enhance anti-tumor efficacy. An in-depth study of the biological mechanisms of oxidized sterols will not only enhance our understanding of the complexity of the tumor immune microenvironment but may also reveal new therapeutic targets, providing innovative strategies for tumor immunotherapy.
Review • Journal
|
GPR183 (G Protein-Coupled Receptor 183)
over1year
Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity. (PubMed, J Med Chem)
The new GPR18 agonists showed minimal species differences, while THC acted as a weak partial agonist at the mouse receptor. The newly discovered compounds represent the most potent and selective GPR18 agonists reported to date.
Journal
|
GPR183 (G Protein-Coupled Receptor 183) • GPR55 (G Protein-Coupled Receptor 55)
almost2years
First report on chemometrics-driven multilayered lead prioritization in addressing oxysterol-mediated overexpression of G protein-coupled receptor 183. (PubMed, Mol Divers)
Post assessment of true external set prediction capability, the MLR model was deployed to screen 12,449 DrugBank compounds, followed by a screening pipeline involving molecular docking, druglikeness, ADMET, protein-ligand stability assessment using deep learning algorithm, molecular dynamics, and molecular mechanics. The current findings strongly evidenced DB05790 as a potential lead for prospective interference of oxysterol-mediated GPR183 overexpression, warranting further in vitro and in vivo validation.
Journal
|
GPR183 (G Protein-Coupled Receptor 183)
2years
G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia By Regulating Immune Regulation (ASH 2023)
COMPLEMENT, HALLMARK_IL6_JAK_STAT3_SIGNALING, and HALLMARK_IL2_STAT5_SIGNALING pathways were activated, and all of these top 5 activated pathways were associated with immune regulation. GPR183 plays a prognostic factor in Acute Myeloid Leukemia by regulatingimmune regulation
GPR183 (G Protein-Coupled Receptor 183)
over2years
Single-cell transcriptomics reveals tumor-infiltrating B cell function after neoadjuvant pembrolizumab and chemotherapy in non-small cell lung cancer. (PubMed, J Leukoc Biol)
Multiplex immunofluorescence and flow cytometry experiments in an additional cohort of 22 treatment-naïve and 30 IIIA/IIIB NSCLC patients treated with neoadjuvant chemoimmunotherapy verified these findings. Overall, our analysis revealed the functions of TIBs and their potential effect on clinical treatment in NSCLC.
Journal
|
GPR183 (G Protein-Coupled Receptor 183)
|
Keytruda (pembrolizumab)